Sagimet Biosciences Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Sagimet Biosciences Inc. (SGMT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Sagimet Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.69M, a 130.98% increase year-over-year.
- Sagimet Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.84M, a 24.93% increase year-over-year.
- Sagimet Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.69M, a 9.18% increase year-over-year.
- Sagimet Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.60M, a 10.28% increase year-over-year.
- Sagimet Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $6.45M, a 21.96% increase from fiscal 2024.
- Sagimet Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $5.29M, a 5.97% increase from fiscal 2023.
- Sagimet Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $4.99M, a 165.43% increase from fiscal 2022.
- Sagimet Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.88M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.69M 10-Q · filed 2026-08-11 | $5.53M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $1.84M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $6.45M 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $1.69M 10-Q · filed 2025-11-13 | $3.29M derived: sum of 2 quarters · filed 2026-08-11 | $4.76M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $1.60M 10-Q · filed 2026-08-11 | $3.07M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $1.47M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $5.29M 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $1.55M 10-Q · filed 2025-11-13 | $3.00M derived: sum of 2 quarters · filed 2025-11-13 | $3.75M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.45M 10-Q · filed 2025-11-13 | $2.21M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $759.00K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $4.99M 10-K · filed 2025-03-12 | |||
| 2023-09-30 | $1.85M 10-Q · filed 2024-11-14 | $2.91M derived: sum of 2 quarters · filed 2024-11-14 | $3.68M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $1.06M 10-Q · filed 2024-11-14 | $1.82M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $767.00K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $1.88M 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $389.00K 10-Q · filed 2023-11-13 | $772.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.16M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $383.00K 10-Q · filed 2023-11-13 | $770.00K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $387.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |